Multiple Sclerosis Care Standards: What NICE NG220 Requires of Support Staff

Multiple sclerosis (MS) presents a different care challenge to the progressive, steadily-declining conditions more commonly covered in residential and home care training: it's typically relapsing and fluctuating, meaning a person's needs can change significantly within weeks, not just over years. NICE guideline NG220 sets out the current standard for managing MS in adults, and several of its specific recommendations have direct, practical implications for care and support staff rather than specialist neurology teams alone.

Fatigue isn't automatically "MS fatigue" — it needs proper assessment

NG220 is specific that fatigue assessment should identify its actual cause before treatment is planned, since fatigue in someone with MS can stem from the condition itself, from other MS symptoms such as pain, spasticity or bladder dysfunction disrupting sleep, or from medication side effects. Management is built around personalised discussion covering energy conservation strategies, a review of lifestyle factors, and stress-reduction approaches including mindfulness and cognitive behavioural techniques. For people with moderate mobility impairment — specifically an EDSS (Expanded Disability Status Scale) score of 4 or above — NG220 recommends considering a supervised programme combining aerobic activity, moderate progressive resistance exercise and cognitive behavioural techniques together, rather than exercise or psychological support alone. The guideline is also clear about what not to use: vitamin B12 injections and hyperbaric oxygen therapy are specifically advised against for MS fatigue, despite being used in some settings.

Recognising and responding to spasticity

NG220 describes spasticity through its practical presentation: involuntary muscle movements (spasms) and muscle stiffness that cause functional difficulty. Before treatment, services should assess for contributing factors that can worsen spasticity — infections, poor posture and untreated pain among them — since addressing these can reduce symptoms without medication change. Where treatment is needed, oral baclofen is the first-line option, introduced with gradual dose increases over at least two weeks, with gabapentin considered as a second-line option if baclofen isn't effective. One nuance worth flagging to care staff directly: some people with MS rely on a degree of spasticity for postural support and stability when standing or transferring, so reducing spasticity pharmacologically can, in some cases, paradoxically increase functional disability — a reason individual response needs monitoring rather than assuming more treatment is always better.

Bladder and bowel dysfunction sits within the wider review, not a separate pathway

NG220 addresses bladder and bowel dysfunction as part of a person's comprehensive MS review rather than setting out a fully separate MS-specific protocol, instead pointing to NICE's general guidance on urinary and faecal incontinence for detailed management. For care staff, the practical takeaway is that bladder and bowel symptoms should be raised and reviewed as part of the person's overall MS care plan, not treated as an unrelated, lower-priority issue to be addressed separately or only when it becomes severe.

The annual comprehensive review — what it covers

NG220 requires a mandatory annual comprehensive assessment carried out by MS-trained professionals, covering mobility, cognition, fatigue, depression, sexual function, bladder and bowel function, pain, and respiratory status, alongside tracking of disease progression and evaluation of social care needs. For a care service supporting someone with MS, this annual review is a specific, checkable compliance point: has it actually happened in the last 12 months, and has it covered this full range of domains, rather than only the symptoms most visibly affecting day-to-day care.

Why MS needs its own staff competency, distinct from other progressive conditions

Because MS symptoms can fluctuate — sometimes significantly improving between relapses — care staff trained primarily on steadily progressive conditions can misread a genuine flare-up as a one-off bad day, or conversely assume a period of improvement means support needs have permanently reduced. Recognising MS's relapsing-remitting pattern, and knowing when to flag a change for clinical review rather than simply adjusting care informally, is a distinct competency that general neurological-conditions training doesn't automatically cover.

Frequently asked questions

What is EDSS, and do care staff need to calculate it themselves?
EDSS (Expanded Disability Status Scale) is a clinical scoring tool used by neurology teams to quantify disability level in MS; care staff don't calculate the score themselves, but understanding what an EDSS 4+ classification means practically helps interpret care plan guidance that references it.

Should care staff adjust support levels during a relapse without waiting for clinical review?
Immediate practical support should flex to match a person's current needs during a relapse, but any change to the person's formal care plan or treatment approach should still involve clinical review rather than being made informally and left unreviewed.

How is this different from general progressive-neurological-condition training?
MS's fluctuating, relapsing-remitting pattern is the key distinguishing feature — unlike the steadier progression seen in conditions like Parkinson's, covered in our guide to Parkinson's Disease care training, MS care requires staff to recognise and respond to significant short-term symptom changes rather than planning around gradual, predictable decline.

MS-specific symptom recognition and review-cycle awareness is a distinct CPD competency for care and support staff. Explore Learnsignal's CPD courses to keep this training current.